Related Experiment Video
Updated: Jul 14, 2026

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
Published on: April 9, 2014
Should antiretroviral therapy be started earlier?
1Division of Infectious Diseases, Johns Hopkins University School of Medicine, 1830 East Monument Street, Room 443, Baltimore, MD 21205, USA. jgallant@jhmi.edu
Current HIV treatment guidelines suggest delaying antiretroviral therapy (ART) until CD4 counts are low. However, newer, safer ART and new data show starting treatment earlier improves outcomes and is cost-effective.
Area of Science:
- Immunology
- Virology
- Public Health
Background:
- Current HIV treatment guidelines recommend deferring antiretroviral therapy (ART) until CD4 counts are between 200-350 cells/mm³.
- Antiretroviral therapy has evolved, becoming simpler, less toxic, and more forgiving of missed doses.
Purpose of the Study:
- To evaluate the benefits of initiating ART at higher CD4 cell counts.
- To determine if earlier ART initiation leads to better patient outcomes and cost-effectiveness.
Main Methods:
- Review of longer-term follow-up data from clinical cohorts.
- Analysis of virologic and immunologic responses to early versus deferred ART initiation.
- Assessment of treatment tolerability and cost-effectiveness.
Main Results:
- Longer-term data indicate better outcomes when ART is initiated at higher CD4 cell counts.
- Early ART initiation demonstrates superior virologic and immunologic responses.
- Early therapy is better tolerated and proves cost-effective.
Conclusions:
- Recent clinical developments and data support a shift towards earlier initiation of ART for HIV management.
- Earlier ART initiation is associated with improved health outcomes and economic benefits.
More Related Videos
Related Concept Videos
Retrovirus Life Cycles
Inhibitors of Virion Maturation and Assembly
Retroviruses
Antiviral Nucleoside Inhibitors
Inhibitors of Viral Protein Synthesis
Sexually Transmitted Infections

